Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A | Q12879 | 9/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.64 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17958202 | 0.91 | GRIN2A (0.62) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16637168 | 0.85 | GRIN2A (0.66) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16637050 | 0.84 | GRIN2A (0.64) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16636830 | 0.84 | GRIN2A (0.68) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16636616 | 0.82 | GRIN2A (0.66) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16645966 | 0.82 | GRIN2A (0.60) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16636662 | 0.82 | GRIN2A (0.65) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16636443 | 0.80 | GRIN2A (0.66) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16637123 | 0.80 | GRIN2A (0.77) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16636695 | 0.80 | GRIN2A (0.62) | GRIN2AGRIN1GRIA2MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015052226-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |